# DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

> **NCT04258371** · PHASE2 · UNKNOWN · sponsor: **University Health Network, Toronto** · enrollment: 50 (estimated)

## Conditions studied

- Cardiovascular Risk Factor

## Interventions

- **DRUG:** Dapagliflozin 10 MG
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04258371
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-10
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-05-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04258371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04258371, "DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04258371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*